Associated tags: Pharmaceutical industry, Opioid, Ketamine, MD, Patient, Stevanato Group, Pain management, IV, Fine chemical, Pain
Locations: CALIFORNIA, DISTRICT OF COLUMBIA, NEW YORK, NEW YORK CITY, UNITED STATES, PHILADELPHIA
SANTA BARBARA, Calif., Jan. 9, 2023 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued patent 11,534,454 titled Complexing Agent Salt Formulations of Pharmaceutical Compounds.
Key Points:
- SANTA BARBARA, Calif., Jan. 9, 2023 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued patent 11,534,454 titled Complexing Agent Salt Formulations of Pharmaceutical Compounds.
- Bexson's formulation technology, branded as SEVALENT™, is the basis for the Company's lead therapy utilizing ketamine for post-operative pain management.
- "This patent is critical in protecting our novel salt formulation, SEVALENT™, across an extensive range of therapeutic areas," commented Jeffrey Becker, MD, Chief Scientific Officer.
- Additionally, management believes its BB106 formulation technology can be utilized to address various mental health indications.
Retrieved on:
Thursday, October 20, 2022
Quality of life,
CA,
Parenteral Drug Association,
NYSE,
Biotechnology,
Patient,
Program,
Ketamine,
Group,
PDA,
Opioid,
Stevanato Group,
Drug delivery,
Biomedicine,
Solution,
Engineering,
Leadership,
Fine chemical,
Pharmaceutical industry SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.
Key Points:
- SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.
- This award recognizes the collaboration between Bexson Biomedical and Stevanato Group to optimize Stevanato Group's innovative wearable device On Body Delivery System (OBDS) with Bexson's formulation technology.
- "It is an honor for Stevanato Group to receive this award, which recognizes the long collaboration with Bexson," adds Stevanato Group's, Paolo Golfetto.
- Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.
Retrieved on:
Tuesday, September 20, 2022
Faculty,
Ketamine,
Invention,
United States Air Force Scientific Advisory Board,
Nobel Prize,
MIT,
CEO,
Opioid,
National Medal,
SAB,
Technology,
Biotechnology,
Multimedia,
Army Science Board,
Paganini Competition,
Pharmaceutical industry "We are excited to have Dr. Langer join our Scientific Advisory Board as a world leader in new biotechnology advancements and inventions who understands the complexities of the regulatory pathway for such advancements given his service as Chairman of the FDA Science Board."
Key Points:
- "We are excited to have Dr. Langer join our Scientific Advisory Board as a world leader in new biotechnology advancements and inventions who understands the complexities of the regulatory pathway for such advancements given his service as Chairman of the FDA Science Board."
- "I am very enthusiastic about joining Bexson's Scientific Advisory Board and I believe Bexson's formulation technology is a significant breakthrough that will allow small molecule therapies to be delivered subcutaneously in a controlled and efficacious manner," commented Dr. Langer.
- He served as both a member and Chairman of the United States Food and Drug Administration's Science Board.
- Bexson Biomedical, Inc. is a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions through new formulations designed for subcutaneous delivery.
Retrieved on:
Thursday, September 15, 2022
IV,
Ketamine,
MD,
Company,
Patient,
CEO,
USPTO,
Technology,
Opioid,
Patent,
Multimedia,
Pharmaceutical industry,
Fine chemical Bexson's formulation platform, branded as SEVALENTTM, is the basis for the Company's lead ketamine therapy, BB106.
Key Points:
- Bexson's formulation platform, branded as SEVALENTTM, is the basis for the Company's lead ketamine therapy, BB106.
- The Company believes this patent allowance expands the potential utility of its formulation technology, SEVALENTTM, to other small molecules.
- "The allowance is significant as it protects our novel salt formulation technology across a broad platform of therapeutic areas," commented Jeffrey Becker, MD, Chief Scientific Officer.
- Bexson Biomedical, Inc. is a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions through new formulations designed for subcutaneous delivery.
Psychiatry,
Becker,
CEO,
Pain management,
Stevanato Group,
MD,
Neuropsychiatry,
Opioid,
Multimedia,
Conference,
Pharmaceutical industry,
Online shopping Becker will contribute to a panel exploring breakthrough innovations and investment opportunities across psychedelics and psychiatry.
Key Points:
- Becker will contribute to a panel exploring breakthrough innovations and investment opportunities across psychedelics and psychiatry.
- Then, co-founder and CEO, Gregg Peterson, will give a corporate update at the H.C. Wainwright 1stAnnual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond on June 27th, also in New York.
- Peterson will present Bexson's continued strategy for the delivery of psychedelic therapies for a variety of indications through its unique subcutaneous formulation technology and wearable delivery platform.
- Bexson is developing a pre-filled, pre-sterilized pump system in conjunction with Italian drug delivery and medical device manufacturer, Stevanato Group.
Pain,
Subcutaneous tissue,
Nausea,
Drug development,
Stevanato Group,
Multimedia,
Pain management,
Psychedelic drug,
Conference,
Technology,
Opioid,
Vomiting,
MD,
Pharmaceutical industry,
Medical device SANTA BARBARA, Calif., May 23, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, will present details on its R&D pipeline combining wearable delivery devices with subcutaneous formulation technology.
Key Points:
- On May 23rd, the Arrowhead Publishers' 2nd-annual Psychedelic Therapeutics & Drug Development Conference will be held near Washington D.C. Bexson Co-founder and Chief Science Officer, Jeffrey Becker, MD, will discuss Bexson's strategy for the delivery of psychedelic therapies for a variety of indications through its unique subcutaneous formulation technology and wearable delivery platform.
- Bexson has applied this same technology to a number of potential psychedelic and empathogen therapies.
- This work applies Bexson's formulation innovation to a wide variety of small molecules for pain, addiction and mental health indications.
- For more information about the Arrowhead Publishers' 2ndannual Psychedelic Therapeutics & Drug Development Conference visit: https://psychedelics-conference.com/
Bexson Biomedical, Inc. is a research stage company developing therapies for a wide variety of pain management, addiction and mental health disorders.
Retrieved on:
Wednesday, March 16, 2022
Doctor of Philosophy,
MD,
PH,
Technology,
University,
Patient,
Ketamine,
Dow University of Health Sciences,
Pain,
Multimedia,
Skin,
Opioid,
Excipient,
Company,
Tissue,
Subcutaneous tissue,
Research,
Bird,
NMDA,
MDPI,
Science,
Pain management,
Pharmaceutical industry SANTA BARBARA, Calif., March 16, 2022 /PRNewswire/ --Bexson Biomedical, Inc., a company developing subcutaneously delivered therapies for pain management, addiction and mental health disorders, announced today the publication of a peer-reviewed paper in MDPI describing the company's novel formulation technology, applied to ketamine.
Key Points:
- SANTA BARBARA, Calif., March 16, 2022 /PRNewswire/ --Bexson Biomedical, Inc., a company developing subcutaneously delivered therapies for pain management, addiction and mental health disorders, announced today the publication of a peer-reviewed paper in MDPI describing the company's novel formulation technology, applied to ketamine.
- The article, Three Birds, One Excipient ,was co-authored by Jason Wallach, James Gamrat, Rebekah Jauhola-Straight, Jeffrey Becker, and Thomas Eckrich.
- The research describesthe development of Bexson Biomedical'snovel technologydesigned to optimize the pH and osmolality of drug solutions for subcutaneous delivery.
- Bexson Biomedical, Inc. is a research stage company developing BB106, a ketamine therapy for pain management and mental health disorders.
Retrieved on:
Thursday, November 18, 2021
Patient,
Adoption,
Stevanato Group,
Depression (mood),
Pain,
Technology,
Suicidal ideation,
Hand,
MD,
Pain management,
Ketamine,
IV,
Program,
Depression,
Physician,
Treatment,
Medicine,
FDA,
Therapy,
Growth,
Multimedia,
Pharmaceutical industry,
Medical device With this milestone reached, Bexson is expanding its ketamine development program to address mental health conditions such as Treatment Resistant Depression and Suicidality.
Key Points:
- With this milestone reached, Bexson is expanding its ketamine development program to address mental health conditions such as Treatment Resistant Depression and Suicidality.
- Bexson's patented formulation, BB106, is a ketamine therapy delivered via a wearable, subcutaneous patch pump, in development withleading medical device manufacturer, Stevanato Group.
- "We are pleased with the clear guidance we received from FDA regarding our preclinical and clinical programs developing BB106," said Gregg Peterson, Bexson Biomedical CEO.
- The company is designing a ketamine therapy with high bioavailability and dynamic dosing profiles that can closely match intravenous ketamine administration.
Psychoactive drugs,
Drugs,
Neurochemistry,
Arylcyclohexylamines,
Dissociative drugs,
Ketones,
Nicotinic antagonists,
Sedatives,
Ketamine,
United States patent law,
Pain management,
Patent b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.
Key Points:
- b'SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ -- Bexson Biomedical, Inc., aresearch-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat.
- 10,973,780, describing pharmaceutical formulations and treatment methods including the company\'s BB106 ketamine therapy.
- This patent represents Bexson\'s first application of these innovations to enable a subcutaneous ketamine delivery platform designed for management of pain disorders and mental health conditions.
- The patent process is a long road and we are pleased to see this first one be issued," said Gregg Peterson, Bexson co-founder and CEO.\nThe company is engaging FDA to prepare for clinical trials evaluating its patented ketamine formula delivered subcutaneously.
As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable infusion device for its BB106 therapy, in partnership with Italian drug containment solution and medical device manufacturer, Stevanato Group.
Key Points:
- As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable infusion device for its BB106 therapy, in partnership with Italian drug containment solution and medical device manufacturer, Stevanato Group.
- Moberg brings 30+ years of expertise to Bexson, combining medical device innovation with a deep understanding of combination product development programs.
- With the addition of Moberg, Bexson is expanding its drug delivery program to develop solutions for other drug therapies, where subcutaneous delivery and dosing control provide distinct advantages.
- Controlled delivery with a wearable pump can help solve limitations in dosing profile, bioavailability, pharmacokinetics, diversion risk and GI side effects.
